Lindsay Rosenwald’s Impact
Dr. Lindsay A Rosenwald, coordinates work with that group of companies which is mostly concerning investment banking, asset supervision, plus direct investing and venture capital in the life-science and biotechnological business. The organization uses a mixture of national and also foreign hedge funds along with private equity for the purpose of managing their investor assets. Added to that Dr. Lindsay Rosenwald has obtained a membership with the Managing Member of Orion Biomedical Fund, LP and the Orion Biomedical Offshore Fund, LP. Both of these associations are participating in Financing. For more than 20 years, Dr. Lindsay Rosenwald has participated as a Wall Street entrepreneur in biotechnology. He has started and re-capitalized dozens of private and public life-sciences and biotechnology organizations. The portfolio companies have so far created three new chemical agents that have been approved by the FDA and they presently have a sizeable number of compounds that are even now undergoing clinical trials. One such portfolio company known as PolaRx BioPharmaceuticals, Inc., has been awarded a final marketing approval for a leukemia compound acknowledged as arsenic trioxide. This was accomplished only 30 months, an industry record, after the medication of the very first patients was done in a corporate clinical testing. 5 Other than Cougar Biotechnology, Dr. Lindsay Rosenwald has in addition taken it upon himself to either support or initiate such companies as Bradley Pharmaceuticals, Inc., Repligen Corporation, Avigen, Inc., Cardiome Pharma Corp., Neose Technologies Inc., Biocryst Pharmaceuticals, Inc, Cypress Bioscience, Inc., Genta, Inc, Discovery Laboratories, Inc., Indevus Pharmaceuticals, Inc., Keryx Biopharmaceuticals, Inc., Cell Therapeutics, Inc., and Hudson Health Sciences, Inc.
In relation to his learning history, Dr. Rosenwald was a graduate from Abington High School, in the southeast vicinity of Pennsylvania, back in 1973. The future doctor and business man went on to graduate Beta Gamma Sigma with a degree in Finance and Economy from Pennsylvania State University in 1977. After that, he discovered a trade as an independent management consultant, laboring for various health care establishments during the years 1977 to 1979 and then entering himself into the Temple University School of Medicine. He graduated from Temple in 1983 and soon afterward received an internship at the Abington Medical Hospital, staying in the private medicine system until the year 1986. Dr. Lindsay Rosenwald then moved on to Wall Street in order to unite his economic and medical skills and function as a medical doctor/financial analyst.
Dr. Rosenwald’s Career
Dr. Lindsay A. Rosenwald presented himself as a corporate finance managing director for D.H. Blair & Company, back in 1988. This was a privately owned investment based organization. There, he was made the lead of a party of three physician-financiers that sorted through the medical community for any new and viable advancements that could make use of private investment. They located various medical schools, universities, hospitals, drug companies, research groups, and scientific firms. He dealt with the biotechnology and bioresearch disciplines. Dr. Rosenwald serves on the Columbia-Presbyterian Health Sciences Advisory Counsel and in the 2002 article edition of Genetic Engineering News he was considered number one in the list of 100 Molecular Millionaires having a worth of $617,721,671. Dr. Lindsay Rosenwald operated on the Keryx Biopharmaceutical, Inc board of directors from 2002 to 2006. He left in order to give added time laboring in the biotechnology area. Cougar Biotechnology, purchased by Johnson & Johnson in 2009, is another company that was originally created by Dr. Rosenwald and was based exclusively on abiraterone acetate. Abiraterone Acetate, even though it had not yet arrived at phase III in clinical testing trials, was presenting so much potential in the therapy and management for prostate cancer that Johnson & Johnson made a short-term union bid and acquirement for the Cougar Biotechnology corporation for $1 billion. Dr. Lindsay Rosenwald, apart from the many ventures which have imparted financing and resources to portfolio companies, has also founded the Rosenwald Foundation. This is a nonprofit establishment that has been doing well in securing millions of dollars in aid of scores of medical and scientific instruction institutions.
Related posts: